Table 1

Summary of patient demographics and dosimetry

Gender/AgeTumor TypeBaseline BilirubinWeightSurface AreaDose
yr mg/dl kg m2 μCi mg/m2 mg/kg
Patient
 1Male/73Lung0.3109.12.293.0113.01.0
 2Male/67Colon0.9 89.12.091.1129.41.5
 3Male/51Colon0.7 78.62.093.6130.31.7
 4Male/70Esophageal0.4 98.22.294.1112.91.1
 51-a Female/64Bile duct0.7 84.41.993.3118.71.4
 6Female/74Endometrial0.4 88.02.093.2121.61.4
 71-b Female/52Lung0.5 52.71.693.6117.02.2
 8Female/71Ovarian0.6 83.22.192.0116.01.4
Males (n = 4)
 Mean ± S.D.0.6 ± 0.393.8 ± 13.02.1 ± 0.193.0 ± 1.3121.4 ± 9.81.3 ± 0.3
 % CV5013.94.91.48.021.4
Females (n = 4)
 Mean ± S.D.0.6 ± 0.177.1 ± 16.41.9 ± 0.293.0 ± 0.7118.3 ± 2.41.6 ± 0.4
 % CV1721.211.20.82.125.8
All Patients (n = 8)
 Mean ± S.D.0.6 ± 0.285.4 ± 16.32.0 ± 0.293.0 ± 1.0119.9 ± 6.81.5 ± 0.4
 % CV3319.19.51.05.724.6
  • % CV, percent coefficient of variation.

  • 1-a Patient had bile duct t-tube.

  • 1-b Patient was a smoker.